Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opinion & Analysis iShares Biotechnology ETF IBB

The fund seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on The NASDAQ Stock Market (NASDAQ). The fund seeks to track the investment results of the NASDAQ Biotechnology Index (the Underlying Index), which contains securities of companies listed on NASDAQ that are classified according to the Industry Classification Benchmark as... see more

Opinion & Analysis (NDAQ:IBB)

Major funds betting on Trump sector

The Life Sciences Report February 28, 2017

Investing in life sciences under the Trump presidency

The Life Sciences Report February 17, 2017

Regeneus hits the fast track with major Japanese partnership

The Life Sciences Report February 9, 2017

Can biotech's Trump bump last?

The Life Sciences Report December 5, 2016

Make-or-break: 5 great investment ideas for 2017

Taki Tsaklanos  November 8, 2016

Stock-moving catalysts anticipated for Regeneus in Q4/16

The Life Sciences Report September 30, 2016

Regeneus secures government funding for R&D

The Life Sciences Report September 14, 2016

Embrace low-cap biotech for high gains: Eden Rahim of Next Edge Capital

The Life Sciences Report March 2, 2016

Healthy biotech growth from four seedling stocks

The Life Sciences Report February 12, 2016

Advanced Stem Cell Manufacture Saves Lives and Prints Money: Stewart Washer of Cynata Therapeutics

The Life Sciences Report February 4, 2016

The 2016 Small-Cap Biotech Watchlist Debuts at the Biotech Showcase

The Life Sciences Report January 28, 2016

Making Old Drugs New Again with Specialized Biotech: DURECT Corp.'s James E. Brown

The Life Sciences Report January 28, 2016

The Academic Approach to Biotech Stocks: Alan Leong of BioWatch News

The Life Sciences Report January 21, 2016

A bucket of Canadian stocks set to soar in 2016

The Life Sciences Report January 19, 2016

Growth by Acquisition Is Solid: Russell Stanley of Mackie Research Capital HLTH, CXV, PHM

George S. Mack December 23, 2015

Panelists Select 19 Companies for the 2016 Small-Cap Biotech Watchlist

The Life Sciences Report December 17, 2015

Let Your Biotech Winners Ride into Orbit: Jason Napodano of BioNap Consulting

George S. Mack December 16, 2015

How to Get Your Piece of the Growing $186B Biomarine Industry: BICA's Pierre Erwes

JT Long December 9, 2015

Oppenheimer's Rohit Vanjani: Finding Profit in the Generic Drug Pricing Wars

George S. Mack November 18, 2015

Raymond James Analyst Reni Benjamin: Regenerating Portfolios with Cell Therapies, Antibodies and Small Molecules

George S. Mack November 16, 2015